Executive Summary
Best-in-class ROS1 inhibitor with TRK-sparing selectivity for improved safety and broad mutation coverage
Key Differentiators
- No approved therapy active after dual TRK/ROS1 inhibitors (repotrectinib, taletrectinib)
- Treatment-limiting CNS adverse events with current TRK/ROS1 inhibitors
- Limited durability - crizotinib mPFS only 19.3 months vs lorlatinib mPFS not reached in ALK
zidesamtinib
ROS1 · kinase inhibitor
Target: ROS1
Full NameROS proto-oncogene 1, receptor tyrosine kinase
PathwayROS1 fusion → constitutive kinase activation → tumor growth
Mechanism of Action
Indications: ROS1+ NSCLC (TKI pre-treated)ROS1+ NSCLC (TKI-naïve)
Target Biology
ROS1 is a receptor tyrosine kinase that when fused to various partner genes creates oncogenic fusion proteins driving tumor growth. ROS1 fusions occur in 1-3% of NSCLC patients, typically younger never-smokers.
Clinical Data
ARROS-1 (NCT05118789)
Phase 1/2Design: Global open-label multi-cohort study
Study Populations
| Cohort | N | Description |
|---|---|---|
| Pivotal Safety | 432 | ROS1+ NSCLC treated at RP2D as of March 21, 2025 |
| Tki Pretreated Efficacy | 117 | Treated at RP2D by May 31, 2024 to allow ≥6 months DOR follow-up |
| Tki Naive Preliminary | 35 | TKI-naïve patients with preliminary data |
Safety
- Discontinuation Rate: 2%
- Dose Reduction Rate: 10%
- Peripheral Edema: 29% (Gr3: 3%)
- Key Differentiator: TRK-sparing design avoids CNS toxicity seen with TRK inhibitors
Investment Analysis
Satya Bio Analysis — estimates based on public data and analyst judgment, not sourced from company materials
Key Risks
| Risk | Evidence | Mitigating Factors |
|---|---|---|
| Competition from established TRK/ROS1 inhibitors | — | |
| Commercial execution as first launch | — | |
| Label breadth (TKI-naïve vs TKI-pretreated) | — |
Peak Sales Estimate:
$570M-$855M US; higher with global expansion
Market Opportunity
Catalysts & Upcoming Events
| Event | Timing | Importance | Key Metrics to Watch | Consensus |
|---|---|---|---|---|
| PDUFA target action date | September 18, 2026 | critical | FDA approval decision for ROS1+ NSCLC | — |
| TKI-naïve data maturation | 2026 | high | Durability of 89% ORR in frontline setting | — |